Search
Feed aggregator
Breaking the Cycle of Inflammation in Parkinson’s Disease
Breaking the Cycle of Inflammation in Parkinson’s Disease 7/15/2024
5 Neuro Data Readouts to Watch in the Second Half of 2024
5 Neuro Data Readouts to Watch in the Second Half of 2024 7/15/2024
SignalChem Biotech, World Leader in Kinases, Is Now Part of Sino Biological
SignalChem Biotech, World Leader in Kinases, Is Now Part of Sino Biological 7/15/2024
Opinion: Congress Must Reauthorize FDA Program for Pediatric Rare Diseases
Opinion: Congress Must Reauthorize FDA Program for Pediatric Rare Diseases 7/15/2024
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data 6/7/2024
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm 6/7/2024
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder 6/7/2024
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate 6/7/2024
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24 6/7/2024
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win 6/7/2024
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA 6/7/2024
Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome
Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome 5/7/2024
World Pharma News
- How the cheese-noodle principle could help counter Alzheimer's
- New 'sensor' lets researchers watch DNA repair in real time
- The immune system creates its own targets within viruses
- Targeted drug could benefit young patients with invasive sarcoma
- Next-generation microbiome medicine may revolutionize the treatment of Parkinson's and similar disorders